|Nombre||Título||Pagar||Ejecutado||Año de nacimiento|
|Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M.||CEO & Member of Management Board||628.26k||N/D||1970|
|Mr. Pierre Kemula B.Sc.||MD, CFO & Member of Management Board||611.16k||N/D||1975|
|Dr. Igor Splawski M.Sc., Ph.D.||Chief Scientific Officer & Member of Management Board||411.95k||N/D||1969|
|Dr. Antony Blanc Ph.D.||MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board||372.57k||N/D||1970|
|Dr. Klaus Edvardsen M.D., Ph.D.||MD, Chief Devel. Officer & Member of Management Board||N/D||N/D||1962|
|Mr. Malte Greune Ph.D.||COO & Member of Management Board||N/D||N/D||1965|
|Dr. Sarah Fakih||VP Corp. Communications & Investor Relations||N/D||N/D||N/D|
|Mr. Thorsten Schuller||Head of Corp. Communications||N/D||N/D||N/D|
|Slavica Stevanovic-Heck||Head of HR||N/D||N/D||N/D|
|Dr. Patrick Baumhof||Sr. VP of Technology||N/D||N/D||N/D|
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
La calificación ISS Governance QuickScore de CureVac N.V. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.